Meloni Seema T, Chaplin Beth, Idoko John, Agbaji Oche, Akanmu Sulaimon, Imade Godwin, Okonkwo Prosper, Murphy Robert L, Kanki Phyllis J
Department of Immunology & Infectious Diseases, Harvard T. H. Chan School of Public Health, 651 Huntington Avenue, FXB 405, Boston, 02115, MA, USA.
University of Jos, Jos, Plateau State, Nigeria.
AIDS Res Ther. 2017 Oct 13;14(1):58. doi: 10.1186/s12981-017-0184-5.
For patients on antiretroviral therapy (ART), treatment interruptions can impact patient outcomes and result in the accumulation of drug resistance mutations leading to virologic failure. There are minimal published data on the impact of an ART stock shortage on development of drug resistance mutations (DRMs). In this report, we evaluate data from patients enrolled in the Government of Nigeria National ART Program that were receiving treatment at the time of a national drug shortage in late 2003.
We conducted a cross-sectional evaluation of samples collected between December 2004 and August 2005 from ART patients in virologic failure that either had a treatment interruption or did not during the late 2003 drug shortage period at the Jos University Teaching Hospital (JUTH). Plasma virus was genotyped, sequence data were edited and analyzed, and mutation profiles were categorized to evaluate predicted drug susceptibility. Data were analyzed to examine factors associated with development of resistance mutations. A genotypic sensitivity score to the alternate recommended regimen was computed to assess drug susceptibility if regimens were changed.
A total of 56 patients were included in this evaluation (28 interrupted, 28 uninterrupted). Patients in the interrupted group had more DRMs than those in the uninterrupted group (p < 0.001); interrupted patients were more likely than uninterrupted patients to have one or more TAM-2 mutations (57.1% interrupted vs. 21.3% uninterrupted; p = 0.04). There was a statistically significant difference in resistance to both d4T (53.7% interrupted vs. 17.9 uninterrupted; p = 0.011) and AZT (64.3% interrupted vs. 25.0% uninterrupted; p = 0.003) by drug interruption status. Examining genotypic sensitivity scores, we found that 67.9% of the interrupted patients, as compared to 25.0% of the uninterrupted patients, did not have full susceptibility to one drug in the regimen to which guidelines recommended they be switched (p = 0.001).
In this small observational study, we found evidence of a difference in resistance profiles and ART susceptibility between those that were stocked-out of drug versus those that were not. We believe that these data are relevant for many other low- and middle-income countries (LMIC) that also experienced similar ART shortages as they rapidly scaled up their national programs.
对于接受抗逆转录病毒治疗(ART)的患者,治疗中断会影响患者的治疗效果,并导致耐药突变的积累,进而导致病毒学失败。关于ART药物短缺对耐药突变(DRM)产生的影响,公开数据极少。在本报告中,我们评估了尼日利亚政府国家ART项目中登记的患者的数据,这些患者在2003年末全国药物短缺时正在接受治疗。
我们对2004年12月至2005年8月期间从乔斯大学教学医院(JUTH)收集的处于病毒学失败状态的ART患者样本进行了横断面评估,这些患者在2003年末药物短缺期间有的经历了治疗中断,有的没有。对血浆病毒进行基因分型,编辑并分析序列数据,对突变谱进行分类以评估预测的药物敏感性。分析数据以检查与耐药突变发生相关的因素。计算对替代推荐方案的基因型敏感性评分,以评估如果改变治疗方案时的药物敏感性。
本评估共纳入56例患者(28例有治疗中断,28例无治疗中断)。治疗中断组的DRM比未中断组更多(p<0.001);治疗中断的患者比未中断的患者更有可能出现一种或多种TAM-2突变(57.1%有治疗中断vs.21.3%无治疗中断;p=0.04)。根据药物中断状态,对司他夫定(d4T)(53.7%有治疗中断vs.17.9%无治疗中断;p=0.011)和齐多夫定(AZT)(64.3%有治疗中断vs.25.0%无治疗中断;p=0.003)的耐药性存在统计学显著差异。检查基因型敏感性评分时,我们发现67.9%的治疗中断患者,与25.0%的未中断患者相比,对指南建议他们转换使用的方案中的一种药物没有完全敏感性(p=0.001)。
在这项小型观察性研究中,我们发现了药物短缺患者与未短缺患者之间在耐药谱和ART敏感性方面存在差异的证据。我们认为这些数据与许多其他低收入和中等收入国家(LMIC)相关,这些国家在快速扩大其国家项目时也经历了类似的ART短缺。